Expert Systems Celebrates Milestone in Clinical Development of Tivoxavir Marboxil, Potential One-Time Influenza Treatment
Expert Systems celebrates a milestone in the clinical development of tivoxavir marboxil, a potential one-time influenza treatment. Developed by Traws Pharma (NASDAQ: TRAW), tivoxavir showed positive topline Phase 1 safety and pharmacokinetic results, supporting its potential as a broad-spectrum flu treatment.
Expert Systems' AI-enabled drug discovery platform helped de-risk and fast-track tivoxavir's development. The study demonstrated good overall tolerability and a pharmacokinetic profile supporting one-time use for flu, including pandemic flu. Tivoxavir is positioned as a potential best-in-class inhibitor of drug-resistant influenza and bird flu viruses.
Phase 2a trials are set to begin in early 2025, aiming to evaluate tivoxavir's potential in reducing flu-related hospitalizations and mortality, especially in vulnerable populations.
Expert Systems celebra un traguardo nello sviluppo clinico di tivoxavir marboxil, un potenziale trattamento per l'influenza da somministrare in una sola volta. Sviluppato da Traws Pharma (NASDAQ: TRAW), il tivoxavir ha mostrato risultati positivi nella fase 1 di sicurezza e farmacocinetica, evidenziando il suo potenziale come trattamento per l'influenza ad ampio spettro.
La piattaforma di scoperta di farmaci abilitata all'IA di Expert Systems ha contribuito a ridurre i rischi e accelerare lo sviluppo del tivoxavir. Lo studio ha dimostrato una buona tollerabilità complessiva e un profilo farmacocinetico che supporta l'uso una tantum per l'influenza, comprese le pandemie influenzali. Il tivoxavir è posizionato come potenziale inibitore di classe migliore contro i virus dell'influenza resistente ai farmaci e dell'influenza aviaria.
I trial di fase 2a sono previsti per iniziare all'inizio del 2025, con l'obiettivo di valutare il potenziale del tivoxavir nel ridurre le ospedalizzazioni e la mortalità correlate all'influenza, specialmente nelle popolazioni vulnerabili.
Expert Systems celebra un hito en el desarrollo clínico de tivoxavir marboxil, un tratamiento potencial para la influenza que se administraría una sola vez. Desarrollado por Traws Pharma (NASDAQ: TRAW), el tivoxavir mostró resultados positivos en la fase 1 de seguridad y farmacocinética, respaldando su potencial como tratamiento de amplio espectro para la gripe.
La plataforma de descubrimiento de fármacos habilitada por IA de Expert Systems ayudó a reducir riesgos y acelerar el desarrollo del tivoxavir. El estudio demostró una buena tolerabilidad general y un perfil farmacocinético que apoya su uso único para la gripe, incluyendo la pandemia de gripe. El tivoxavir se posiciona como un potencial inhibidor de clase superior contra los virus de la influenza resistente a medicamentos y la gripe aviar.
Los ensayos de fase 2a comenzarán a principios de 2025, con el objetivo de evaluar el potencial del tivoxavir para reducir las hospitalizaciones y la mortalidad relacionadas con la gripe, especialmente en poblaciones vulnerables.
Expert Systems는 잠재적인 일회성 인플루엔자 치료제인 티복사비르 마복실의 임상 개발에서 이정표를 세웠습니다. Traws Pharma (NASDAQ: TRAW)에서 개발한 티복사비르는 1상 안전성 및 약물 동태 결과에서 긍정적인 성과를 보여 주며 광범위한 인플루엔자 치료제로서의 가능성을 뒷받침하고 있습니다.
전문 시스템의 AI 기반 약물 발견 플랫폼은 티복사비르의 개발 위험을 줄이고 신속하게 진행할 수 있도록 도왔습니다. 연구는 인플루엔자(팬데믹 인플루엔자 포함)에 대한 일회성 사용을 뒷받침하는 좋은 전반적인 내약성을 보여주었습니다. 티복사비르는 약물 내성이 있는 인플루엔자 및 조류 독감 바이러스의 가능성 있는 적절한 억제제로 자리 잡고 있습니다.
2a상 시험은 2025년 초에 시작될 예정으로, 특히 취약한 인구에서 인플루엔자 관련 입원 및 사망률 감소에 대한 티복사비르의 잠재력을 평가하는 것을 목표로 하고 있습니다.
Expert Systems célèbre une avancée dans le développement clinique de tivoxavir marboxil, un traitement potentiel contre la grippe à administrer en une fois. Développé par Traws Pharma (NASDAQ: TRAW), le tivoxavir a montré des résultats positifs dans la phase 1 de sécurité et de pharmacocinétique, soutenant son potentiel comme traitement anti-grippal à large spectre.
La plateforme de découverte de médicaments propulsée par IA d'Expert Systems a aidé à réduire les risques et à accélérer le développement du tivoxavir. L'étude a montré une bonne tolérance globale et un profil pharmacocinétique soutenant une utilisation unique pour la grippe, y compris la grippe pandémique. Le tivoxavir se positionne comme un inhibiteur potentiel de classe supérieure contre les virus de la grippe résistants aux médicaments et de la grippe aviaire.
Les essais de phase 2a devraient commencer début 2025, visant à évaluer le potentiel du tivoxavir pour réduire les hospitalisations et la mortalité liées à la grippe, en particulier chez les populations vulnérables.
Expert Systems feiert einen Meilenstein in der klinischen Entwicklung von Tivoxavir Marboxil, einer potenziellen Einmalbehandlung gegen Influenza. Entwickelt von Traws Pharma (NASDAQ: TRAW), zeigte Tivoxavir positive Ergebnisse in der Phase-1-Sicherheits- und Pharmakokinetikstudie, die sein Potenzial als breite Influenza-Behandlung unterstützt.
Die KI-unterstützte Arzneimittelentdeckungsplattform von Expert Systems trug dazu bei, das Risiko zu minimieren und die Entwicklung von Tivoxavir zu beschleunigen. Die Studie zeigte eine gute allgemeine Verträglichkeit und ein pharmakokinetisches Profil, das die Einmalanwendung gegen Influenza, einschließlich Pandemiegrippe, unterstützt. Tivoxavir wird als potenzieller Best-in-Class-Inhibitor von medikamentenresistenten Influenza- und Vogelgrippeviren positioniert.
Phase-2a-Studien sollen Anfang 2025 beginnen, um das Potenzial von Tivoxavir zur Verringerung von krankheitsbedingten Krankenhausaufenthalten und Sterblichkeit, insbesondere in gefährdeten Bevölkerungsgruppen, zu bewerten.
- None.
- None.
Expert Systems' advanced AI-enabled drug discovery platform helped de-risk and fast-track tivoxavir's development from discovery to the clinic. Topline Phase 1 results demonstrated good overall tolerability and a pharmacokinetic profile that appears to support tivoxavir's potential use as a one-time treatment for flu, including pandemic flu. The successful outcome of this study positions tivoxavir as a potential best-in-class inhibitor of drug-resistant influenza and bird flu viruses. Phase 2a trials, set to begin in early 2025, will further evaluate tivoxavir's potential to help alleviate the public health burden associated with flu-related hospitalizations and mortality, especially in older adults and vulnerable populations.
"Tivoxavir's successful Phase 1 results are a testament to the power of our AI-enabled platform in accelerating the development of cutting-edge therapies," said Bill Farley, Chief Business Officer at Expert Systems. "Our platform helps de-risks the early stages of drug development, reducing time and costs while ensuring data-driven decisions. We are excited to support Traws Pharma in bringing this innovative flu treatment closer to market."
About Expert Systems, Inc.
Expert Systems, Inc., an advanced accelerator platform, is equipped with a comprehensive, hybrid AI-based system that covers the entire spectrum of preclinical drug discovery and early development phases. This includes target identification, virtual screening, non-clinical and clinical pharmacology, chemical liability assessment, and toxicology. Utilizing a unique combination of proprietary and public databases, Expert Systems employs specialized software tools to evaluate the intellectual property landscape and construct a competitive drug intelligence strategy to de-risk candidate selection for rapid transition from in silico to first-in-human trials. Expert Systems has been pivotal in establishing Seed and Series A companies, organizing and managing over 30 research and development programs across various financial investors and strategic partners in
Media Contact:
Bill Farley
CBO
View original content:https://www.prnewswire.com/news-releases/expert-systems-celebrates-milestone-in-clinical-development-of-tivoxavir-marboxil-potential-one-time-influenza-treatment-302273257.html
SOURCE Expert Systems, Inc.
FAQ
What are the key findings from tivoxavir marboxil's Phase 1 trial for TRAW?
When will Traws Pharma (TRAW) begin Phase 2a trials for tivoxavir marboxil?
How did Expert Systems contribute to the development of tivoxavir marboxil for TRAW?
What is the target of tivoxavir marboxil in treating influenza for TRAW?
